Barbara Brune
Hematology & Oncology · Alexandria, VANPI 1912692831
Payments from drug & device makers
Across 75 payments — averaging $25.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$422
- Novartis$290
- Daiichi Sankyo Inc.$139
- Merck$131
- Regeneron Healthcare Solutions, Inc.$106
- AstraZeneca$76
- plus $742 from 21 others
What the payments were for
- Food & beverage$1,80895%
- Education$995%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 13 | $422 |
| Novartis | 11 | $290 |
| Daiichi Sankyo Inc. | 6 | $139 |
| Merck | 6 | $131 |
| Regeneron Healthcare Solutions, Inc. | 4 | $106 |
| AstraZeneca(2 entities) | 3 | $76 |
| Mirati Therapeutics, Inc. | 2 | $64 |
| Genentech USA, Inc. | 2 | $57 |
| Pharmacosmos Therapeutics Inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Pharmaessentia USA Corporation | 2 | $47 |
| Recordati_rare_diseases_inc. | 2 | $47 |
| Myriad Genetic Laboratories, Inc. | 2 | $43 |
| Taiho Oncology, Inc. | 2 | $42 |
| Ipsen Biopharmaceuticals, Inc | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Coherus Oncology, Inc. | 1 | $32 |
| Exelixis Inc. | 1 | $29 |
| Stemline Therapeutics Inc. | 1 | $28 |
| Rigel Pharmaceuticals, Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $26 |
| Spectrum Pharmaceuticals Inc. | 1 | $24 |
| Eisai Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Shield Therapeutics Inc | 1 | $20 |
| Acrotech Biopharma Inc. | 1 | $19 |
| CTI Biopharma Corp. | 1 | $13 |
How this compares
$1,907 in reported general payments places this provider in the 45th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $14,955 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Alexandria
- Vinni JunejaAlexandria$770K
- Craig PortellCharlottesville$12.9M
- Amanda Gillespie-TwardyRoanoke$12.2M
- Sekwon JangFairfax$11.8M
- Mark FlemingHampton$10M
- Mark KochenderferRoanoke$8.6M
- Mitul GandhiManassas$6.9M
- Michael DansoNorfolk$6.9M
- Jerome GoldschmidtChristiansburg$6.5M
- William IrvinMidlothian$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.